Life Sciences and Healthcare COVID-19 Briefings:

Cross-border: A vaccine for COVID-19: risks and liabilities from an international perspective >

OXYGY: Demonstrating Value: The New World of Life Sciences Podcast >

OXYGY: Embrace Digitalization: The New World of Life Sciences Podcast >

OXYGY: From rigid & risk averse to agile & experimental: The New World of Life Sciences Podcast >

OXYGY: What Pharma Supply Chain Should Learn from the COVID-19 Crisis >

UAE: COVID-19: our series of regulatory legislation trackers for the Life Sciences & Healthcare industry >

Australia: While COVID-19 lockdown restrictions ease enforcement of advertising restrictions for therapeutic goods tighten >

OXYGY: Disruption is here: the new world of life sciences (podcast) >

OXYGY: Five Success factors for effective digital transformation in Pharma >

UK: Our series of COVID-19 regulatory legislation trackers for the Life Sciences & Healthcare industry >

Australia: Export Restrictions on Health Related Products during COVID-19 >

France: ANSM guidance on Data Protection requirements for on-going trials during COVID-19 >

Australia: response to regulation of medical devices during COVID-19 >

China Imposes New Export Restrictions for COVID-19 Medical Products >

Cross-border: Increased leeway for cooperation between Pharma and Medical Equipment companies during the COVID-19 crisis >

Germany: New legislation to fight pandemic may affect granted patents >

Cross-border: EU guidelines on the exercise of the free movement of workers during COVID-19 crisis >

China: A cure for COVID-19? – Don’t make the claim unless it is true >

UK: Public Health Perspectives >

Spain: "State of alarm" and temporary reduction of workforce >